Near infrared light mitigates cerebellar pathology in transgenic mouse models of dementia

Neuroscience Letters

Volumn 591, Issue , 2015, Pages 155-159

  Purushothuman, Sivaraman ^a,b   Johnstone, Daniel M ^a   Nandasena, Charith ^a   van Eersel, Janet ^c   Ittner, Lars M ^c,d   Mitrofanis, John ^a   Stone, Jonathan ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Dementia; Mouse model; Near infrared light; Neuroprotection

Indexed keywords

AMYLOID BETA PROTEIN; CYTOCHROME C OXIDASE; TAU PROTEIN; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEGENERATION; CEREBELLUM; CEREBELLUM CORTEX; CEREBELLUM DISEASE; CLINICAL EFFECTIVENESS; CLINICAL OBSERVATION; CONTROLLED STUDY; DEMENTIA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; LOW LEVEL LASER THERAPY; MOUSE; NEAR INFRARED LIGHT THERAPY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PURKINJE CELL; TREATMENT OUTCOME; AMYLOID PLAQUE; ANIMAL; DISEASE MODEL; GENETICS; INFRARED RADIATION; METABOLISM; MITOCHONDRION; PATHOLOGY; RADIATION RESPONSE; TRANSGENIC MOUSE;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CEREBELLUM; DEMENTIA; DISEASE MODELS, ANIMAL; INFRARED RAYS; MICE, TRANSGENIC; MITOCHONDRIA; OXIDATIVE STRESS; PLAQUE, AMYLOID; PRESENILIN-1; TAU PROTEINS;

EID: 84923362831     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.02.037     Document Type: Article

References (32)

1. Eells J.T., Henry M.M., Summerfelt P., Wong-Riley M.T., Buchmann E.V., Kane M., Whelan N.T., Whelan H.T. Therapeutic photobiomodulation for methanol-induced retinal toxicity. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:3439-3444.
2. Natoli R., Zhu Y., Valter K., Bisti S., Eells J., Stone J. Gene and noncoding RNA regulation underlying photoreceptor protection: microarray study of dietary antioxidant saffron and photobiomodulation in rat retina. Mol. Vision 2010, 16:1801-1822.
3. Oron A., Oron U., Streeter J., de Taboada L., Alexandrovich A., Trembovler V., Shohami E. low-level laser therapy applied transcranially to mice following traumatic brain injury significantly reduces long-term neurological deficits. J. Neurotrauma 2007, 24:651-656.
4. Wu Q., Xuan W., Ando T., Xu T., Huang L., Huang Y.Y., Dai T., Dhital S., Sharma S.K., Whalen M.J., Hamblin M.R. Low-level laser therapy for closed-head traumatic brain injury in mice: effect of different wavelengths. Lasers Surg. Med. 2012, 44:218-226.
5. Xuan W., Vatansever F., Huang L., Wu Q., Xuan Y., Dai T., Ando T., Xu T., Huang Y.Y., Hamblin M.R. Transcranial low-level laser therapy improves neurological performance in traumatic brain injury in mice: effect of treatment repetition regimen. PLoS One 2013, 8:e53454.
6. Moro C., Torres N., El Massri N., Ratel D., Johnstone D.M., Stone J., Mitrofanis J., Benabid A.L. Photobiomodulation preserves behaviour and midbrain dopaminergic cells from MPTP toxicity: evidence from two mouse strains. BMC Neurosci. 2013, 14:40.
7. Peoples C., Spana S., Ashkan K., Benabid A.L., Stone J., Baker G.E., Mitrofanis J. Photobiomodulation enhances nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson's disease. Parkinsonism Related Disord. 2012, 18:469-476.
8. Shaw V.E., Peoples C., Spana S., Ashkan K., Benabid A.L., Stone J., Baker G.E., Mitrofanis J. Patterns of cell activity in the subthalamic region associated with the neuroprotective action of near-infrared light treatment in MPTP-treated mice. Parkinsons Dis. 2012, 2012:296875.
9. Shaw V.E., Spana S., Ashkan K., Benabid A.L., Stone J., Baker G.E., Mitrofanis J. Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment. J. Comp. Neurol. 2010, 518:25-40.
10. De Taboada L., Yu J., El-Amouri S., Gattoni-Celli S., Richieri S., McCarthy T., Streeter J., Kindy M.S. Transcranial laser therapy attenuates amyloid-beta peptide neuropathology in amyloid-beta protein precursor transgenic mice. J. Alzheimers Dis. 2011, 23:521-535.
11. Grillo S.L., Duggett N.A., Ennaceur A., Chazot P.L. Non-invasive infra-red therapy (1072nm) reduces beta-amyloid protein levels in the brain of an Alzheimer's disease mouse model, TASTPM. J. Photochem. Photobiol. B 2013, 123:13-22.
12. Ivandic B.T., Ivandic T. Low-level laser therapy improves vision in patients with age-related macular degeneration. Photomed. Laser Surg. 2008, 26:241-245.
13. Lampl Y., Zivin J.A., Fisher M., Lew R., Welin L., Dahlof B., Borenstein P., Andersson B., Perez J., Caparo C., Ilic S., Oron U. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the neurothera effectiveness and safety trial-1 (NEST-1). Stroke 2007, 38:1843-1849.
14. Purushothuman S., Johnstone D.M., Nandasena C., Mitrofanis J., Stone J. Photobiomodulation with near infrared light mitigates Alzheimer's disease-related pathology in cerebral cortex - evidence from two transgenic mouse models. Alzheimers Res. Ther. 2014, 6:2.
15. Tuby H., Hertzberg E., Maltz L., Oron U. Long-term safety of low-level laser therapy at different power densities and single or multiple applications to the bone marrow in mice. Photomed. Laser Surg. 2013, 31:269-273.
16. Ittner L.M., Fath T., Ke Y.D., Bi M., van Eersel J., Li K.M., Gunning P., Gotz J. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc. Natl. Acad. Sci. U.S.A 2008, 105:15997-16002.
17. van Eersel J., Ke Y.D., Liu X., Delerue F., Kril J.J., Gotz J., Ittner L.M. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc. Natl. Acad. Sci. U.S.A 2010, 107:13888-13893.
18. Franklin K., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 2007, Elsevier, New York, U.S.A.
19. Wallace B.A., Ashkan K., Heise C.E., Foote K.D., Torres N., Mitrofanis J., Benabid A.L. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 2007, 130:2129-2145.
20. Trinchese F., Liu S., Battaglia F., Walter S., Mathews P.M., Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann. Neurol. 2004, 55:801-814.
21. Yan Q., Zhang J., Liu H., Babu-Khan S., Vassar R., Biere A.L., Citron M., Landreth G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 2003, 23:7504-7509.
22. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002, 103:26-35.
23. Bruck W., Bitsch A., Kolenda H., Bruck Y., Stiefel M., Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann. Neurol. 1997, 42:783-793.
24. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K., Jones P.K., Ghanbari H., Wataya T., Shimohama S., Chiba S., Atwood C.S., Petersen R.B., Smith M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2001, 60:759-767.
25. Thal D.R., Rub U., Orantes M., Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
26. Joachim C.L., Morris J.H., Selkoe D.J. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am. J. Pathol. 1989, 135:309-319.
27. Braak H., Braak E., Bohl J., Lang W. Alzheimer's disease: amyloid plaques in the cerebellum. J. Neurol. Sci. 1989, 93:277-287.
28. Lemere C.A., Lopera F., Kosik K.S., Lendon C.L., Ossa J., Saido T.C., Yamaguchi H., Ruiz A., Martinez A., Madrigal L., Hincapie L., Arango J.C., Anthony D.C., Koo E.H., Goate A.M., Selkoe D.J. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat. Med. 1996, 2:1146-1150.
29. Oron A., Oron U., Chen J., Eilam A., Zhang C., Sadeh M., Lampl Y., Streeter J., DeTaboada L., Chopp M. Low-level laser therapy applied transcranially to rats after induction of stroke significantly reduces long-term neurological deficits. Stroke 2006, 37:2620-2624.
30. Rojas J.C., Gonzalez-Lima F. Low-level light therapy of the eye and brain. Eye Brain 2011, 3:49-67.
31. Moro C., Massri N.E., Torres N., Ratel D., De Jaeger X., Chabrol C., Perraut F., Bourgerette A., Berger M., Purushothuman S., Johnstone D., Stone J., Mitrofanis J., Benabid A.L. Photobiomodulation inside the brain: a novel method of applying near-infrared light intracranially and its impact on dopaminergic cell survival in MPTP-treated mice. J. Neurosurg. 2014, 120:670-683.
32. Johnstone D.M., el Massri N., Moro C., Spana S., Wang X.S., Torres N., Chabrol C., De Jaeger X., Reinhart F., Purushothuman S., Benabid A.L., Stone J., Mitrofanis J. Indirect application of near infrared light induces neuroprotection in a mouse model of parkinsonism - an abscopal neuroprotective effect. Neuroscience 2014, 274:93-101.